OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weitzel on Combination Therapies in Breast Cancer

November 26th 2012

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Dr. Renier Brentjens on Genetically-Modified T Cells

November 21st 2012

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, explains the process by which his laboratory at MSKCC genetically modifies immune cells to fight cancer.

Dr. Baselga on pan-PI3K Inhibitors in Breast Cancer

November 20th 2012

JosÃ© Baselga, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the investigation of pan-PI3K inhibitors for patients with metastatic breast cancer.

Dr. Konner on Bevacizumab in Ovarian Cancer

November 16th 2012

Jason A. Konner, MD, from Memorial Sloan-Kettering Cancer Center, explains that one of the main drivers behind research into bevacizumab in ovarian cancer is to identify which patients will benefit the most from the treatment.

Dr. Duncan on Measuring the Success of Patient Navigation

November 15th 2012

Mark D. Duncan, MD, from The Johns Hopkins University School of Medicine, discusses demonstrable metrics that help measure the success of a patient navigation program.

Mary Lou Woodford on CoC Accreditation Compliance

November 15th 2012

Mary Lou Woodford, from the Cancer Resource Foundation, provides guidance on staying compliant with the new patient navigation accreditation standards from the American College of Surgeons Commission on Cancer.

Dr. Debu Tripathy Previews the Phase II GRN1005 Study

November 14th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Dr. Hope Rugo Previews the 2012 SABCS Program

November 13th 2012

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Dr. Oh on Sequencing New Treatments for Prostate Cancer

November 12th 2012

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

Dr. Holcombe on Regorafenib for Colorectal Cancer

November 9th 2012

Randall F. Holcombe, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the oral multikinase inhibitor regorafenib for patients with metastatic colorectal cancer.

Dr. Kantarjian on the Optimal Frontline Treatment for CML

November 8th 2012

Hagop M. Kantarjian, MD, from MD Anderson Cancer Center, discusses the optimal frontline therapy for patients with chronic phase chronic myelogenous leukemia.

Dr. Sekulic on Vismodegib for Basal-Cell Nevus Syndrome

November 6th 2012

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.

Dr. Mamounas on Neoadjuvant Chemo for Breast Cancer

November 5th 2012

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.

Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

November 2nd 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

Dr. Markman Discusses the Phase III AURELIA Trial

October 29th 2012

Maurie Markman, MD, from Cancer Treatment Centers of America, discusses the AURELIA trial that examined the addition of bevacizumab to chemotherapy for women with platinum-resistant recurrent ovarian cancer.

Dr. Rotkowitz on Ipilimumab Plus Dacarbazine for Melanoma

October 26th 2012

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Dr. Aithal on the HERceptin Adjuvant (HERA) Trial

October 25th 2012

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Dr. Cristofanilli Discusses ALK Amplification in IBC

October 23rd 2012

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer

October 23rd 2012

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.